Comparative Pharmacology
Head-to-head clinical analysis: DAPTOMYCIN IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPTOMYCIN IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
DAPTOMYCIN IN 0.9% SODIUM CHLORIDE vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Daptomycin is a cyclic lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and potassium ion efflux, leading to inhibition of protein, DNA, and RNA synthesis, and bacterial cell death.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
4-6 mg/kg intravenously every 24 hours. For Staphylococcus aureus bloodstream infections (bacteremia), including right-sided infective endocarditis, 6 mg/kg intravenously every 24 hours.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal elimination half-life: approximately 8-9 hours in patients with normal renal function; prolonged in renal impairment (up to 28 hours in severe impairment).
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Primarily renal (78% unchanged in urine); biliary/fecal excretion is negligible (<6%).
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte